Mehmet A Baysal
Overview
Explore the profile of Mehmet A Baysal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
33
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fountzilas E, Pearce T, Baysal M, Chakraborty A, Tsimberidou A
NPJ Digit Med
. 2025 Jan;
8(1):75.
PMID: 39890986
The confluence of new technologies with artificial intelligence (AI) and machine learning (ML) analytical techniques is rapidly advancing the field of precision oncology, promising to improve diagnostic approaches and therapeutic...
2.
Valdez B, Tsimberidou A, Yuan B, Baysal M, Chakraborty A, Andersen C, et al.
Int J Mol Sci
. 2024 Sep;
25(17).
PMID: 39273190
Breast and ovarian cancers pose significant therapeutic challenges. We explored the synergistic cytotoxicity of histone deacetylase inhibitors (HDACis), poly(ADP-ribose) polymerase inhibitors (PARPis), and decitabine in breast (MDA-MB-231 and MCF-7) and...
3.
Baysal M, Chakraborty A, Tsimberidou A
J Cancer Immunol (Wilmington)
. 2024 Aug;
6(1):20-28.
PMID: 39119270
The emergence of chimeric antigen receptor T cell (CAR-T cell) therapy has revolutionized cancer treatment, particularly for hematologic malignancies. This commentary discusses developments in CAR-T cell therapy, focusing on the...
4.
Valdez B, Tsimberidou A, Yuan B, Nieto Y, Baysal M, Chakraborty A, et al.
Oncotarget
. 2024 Jun;
15:361-373.
PMID: 38829622
Histone deacetylase inhibitors (HDACi) can modulate the acetylation status of proteins, influencing the genomic instability exhibited by cancer cells. Poly (ADP ribose) polymerase (PARP) inhibitors (PARPi) have a direct effect...
5.
Torrado C, Baysal M, Chakraborty A, Norris B, Khawaja F, Tsimberidou A
Front Immunol
. 2024 May;
15:1366271.
PMID: 38779675
A patient in his 40s with splenic angiosarcoma metastatic to the liver underwent splenectomy, chemotherapy, and partial hepatectomy before being treated on a clinical trial with CTLA4 and PD1 inhibitors....
6.
Tsimberidou A, Baysal M, Chakraborty A, Andersson B
Hum Vaccin Immunother
. 2023 Dec;
19(3):2290356.
PMID: 38114231
To overcome challenges associated with adoptive cell therapy (ACT), we developed a personalized autologous T-cell therapy program. Patients with advanced cancer with HLA-A *02:01 allele and tumor expression of PRAME,...
7.
Bulliard Y, Andersson B, Baysal M, Damiano J, Tsimberidou A
J Hematol Oncol
. 2023 Oct;
16(1):108.
PMID: 37880715
T cell differentiation is a highly regulated, multi-step process necessary for the progressive establishment of effector functions, immunological memory, and long-term control of pathogens. In response to strong stimulation, as...
8.
Tsimberidou A, Kahle M, Vo H, Baysal M, Johnson A, Meric-Bernstam F
Nat Rev Clin Oncol
. 2023 Oct;
20(12):843-863.
PMID: 37845306
Over the past 15 years, rapid progress has been made in developmental therapeutics, especially regarding the use of matched targeted therapies against specific oncogenic molecular alterations across cancer types. Molecular...
9.
Song I, Vo H, Chen Y, Baysal M, Kahle M, Johnson A, et al.
Cancers (Basel)
. 2023 Apr;
15(7).
PMID: 37046628
Advances in molecular technologies and targeted therapeutics have accelerated the implementation of precision oncology, resulting in improved clinical outcomes in selected patients. The use of next-generation sequencing and assessments of...